1. ESMOupdate 2012, Breast and Gynecological Cancers

Prof. Dr. med. Monica Castiglione und Dr. med. Daniel Helbling besprechen die wichtigsten, klinisch relevanten Studien im Bereich Breast and Gynecological Cancer, die am diesjährigen ESMO (European Society for Medical Onocology) Meeting in Wien präsentiert wurden.

Diskutierte Studien:
LBA6_PR: HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up; A. Goldhirsch et al

LBA12: Updated Overall Survival Results from EMILIA, a phase 3 study of trastuzumab emtansine (T-DM1) vs capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC); S. Verma et al

Leave a Reply

Your email address will not be published. Required fields are marked *